ANTICANCER RESEARCH 26: (2006)
|
|
- Agnes Baldwin
- 6 years ago
- Views:
Transcription
1 Diffuse Micronodular Pulmonary Metastasis of Lung Adenocarcinoma Predicts Gefitinib Response in Association with Epidermal Growth Factor Receptor Mutations MAKOTO KOBAYASHI 1, TAMOTSU TAKEUCHI 2, KENTARO BANDOBASHI 1, YOSHIKI UEMURA 1, YASUHIRO OGAWA 3, YUJI OHTSUKI 2 and HIROKUNI TAGUCHI 1 Departments of 1 Hematology and Respiratory Medicine, 2 Tumor Pathology and 3 Tumor Radiology, Kochi Medical School, Kochi University, Nankoku, Kochi , Japan Abstract. Female, non-smoker, Asian ethnicity and adenocarcinoma histology are the major clinical predictors of gefitinib response in non-small cell lung cancer, as shown in previous studies. Recently, response to gefitinib has been associated with epidermal growth factor receptor (EGFR) mutations. Higher rates of mutation were seen in females, patients with adenocarcinomas, the Asian population and never-smokers, which may explain the clinical response predictors. The presence of diffuse micronodular pulmonary metastasis on chest imaging as a novel clinical predictor of its response is proposed here. Two cases of lung adenocarcinomas in men presenting with diffuse micronodular pulmonary metastasis were encountered. Both patients showed a major response to gefitinib. The dramatic reduction of micronodular pulmonary nodules throughout both lungs on computed tomography scans was achieved after treatment for a couple of months with 250 mg of oral gefitinib. In the molecular analysis, one patient had a heterozygous dell746-a750 mutation and the other had a heterozygous L858R EGFR mutation. In conclusion, patients with lung adenocarcinoma, even men, who presented with bilateral diffuse micronodular metastatic spread to the lungs tended to have an activated EGFR mutation. Therefore, they are most likely to receive benefits from molecular target drugs such as gefitinib and possibly erlotinib. Gefitinib (ZD1839, Iressa; AstraZeneca, Osaka, Japan) is a specific inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It has shown favorable efficacy, especially in the treatment of non-small cell lung cancer (NSCLC) (1, 2). Recently, activating mutations of EGFR were found to have a significant association with the response to gefitinib, suggesting the promising role of EGFR mutations as a predictive marker of gefitinib response (3-5). These mutations occurred near the adenosine tri-phosphate (ATP) cleft of the tyrosine kinase domain in which 4-anilinoquinazoline compounds, such as gefitinib, compete with ATP for binding (3, 4). Consequently, gefitinib binding with the ATP cleft abrogates the downstream signal transduction by blocking autophosphorylation, leading to the arrested growth and ultimate apoptosis of cancer cells (3-6). Higher rates of mutation were seen in females, patients with adenocarcinomas, the Asian population and never-smokers, which may explain the clinical response predictors (3-9). During our practice of treating NSCLC with gefitinib, we noticed that a diffuse micronodular pattern of pulmonary metastasis might be another clinical predictor of response in patients with lung cancer in the Japanese population. An investigation of the pertinence of our hypothesis is attempted here by describing case reports and their EGFR mutational analysis. Case Reports Correspondence to: Dr. Makoto Kobayashi, MD, Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi , Japan. Tel: , Fax: , kmakoto@med.kochi-u.ac.jp Key Words: Diffuse micronodular opacities, gefitinib, EGFR mutation, bronchioloalveolar cell carcinoma. Patient 1. A 40-year-old salesman and former light smoker developed a cough and general fatigue one month before hospital admission. At the end of June 2004, a chest radiograph and computed tomography (CT) scan taken in a local hospital revealed a nodule with diameter of 2.0 cm in the apical segment of the lower lobe of the right lung and /2006 $
2 numerous micronodular opacities on both lungs. On July 1, 2004, he was referred to Kochi Medical School Hospital, Japan, for further examination. Bronchoscopy with brushing to collect samples for cytological analysis demonstrated adenocarcinoma cells in the apical segment of his right lower lobe. His condition was diagnosed as pulmonary adenocarcinoma with multiple pulmonary metastases. A systematic survey showed no metastasis other than in the lungs. Arterial blood gas testing showed a PaO 2 of 82.6 mmhg and a PaCO 2 of 42.5 mmhg for the inhalation of room air. Regarding treatment, the patient wanted to receive a molecular target drug, gefitinib, instead of conventional platinum-containing chemotherapy. He began to take gefitinib soon after hospital admission. The diffuse micronodular opacities on the chest radiograph began to disappear after one week. Thereafter, skin eruptions involving his face, especially surrounding his mouth and the upper trunk were observed as an adverse effect, but were tolerable during the entire course of his illness. Two months after the start of the therapy, the maximum reduction in number and size of micronodular opacities was attained with associated shrinkage of the primary tumor on CT scans (Figure 1 A, B). Eight months after the start of gefitinib therapy, the patient developed right pleural effusion and multiple liver metastases as recurrence of the disease and was admitted to our hospital for a change in therapy. At that time, a portion of the pleural effusion was kept for later DNA analysis after obtaining informed consent. Gefitinib therapy was stopped and one cycle of chemotherapy using the combination of carboplatin and paclitaxel was instituted. However, the patient refused continuation of chemotherapy and requested a transfer to another hospital, where he died 2 months later of progressive disease. Patient 2. A 51-year-old male construction worker was admitted to our hospital with increasing diffuse micronodular opacities on both lungs. He had regularly undergone annual check-ups and had undergone chest radiograph examination, once annually, for 3 years before the first admission. An abnormal chest radiograph result was followed by CT imaging. The patient was suspected of having pneumoconiosis and was advised to stop smoking. Due to the substantial increase in micronodular opacities on both lungs over the previous 2 years, he was referred to our hospital for further examination in mid-december Bronchoscopy was immediately performed. A transbronchial lung biopsy and bronchoalveolar lavage fluid cytology showed the presence of suspected adenocarcinoma cells. In the meantime, he did not report discomfort from any respiratory symptoms. Arterial blood gas testing showed a PaO 2 of mmhg and a PaCO 2 of 39.9 mmhg for the inhalation of room air. For the purpose of establishing the diagnosis, video-assisted thoracoscopic surgery (VATS) was performed in January Partial resection of the middle lobe demonstrated welldifferentiated papillary adenocarcinoma with multiple pulmonary metastases. No evidence of either pneumoconiosis or of any other kind of interstitial pneumonia was found in the remaining resected lung tissue. A systematic survey showed no metastasis except for in the lungs, as with Patient 1. Combination chemotherapy using carboplatin and paclitaxel was started. The first cycle of chemotherapy was performed on an in-patient basis. The remaining 5 cycles of chemotherapy were continued on an out-patient basis, with minor response of the primary tumor and no change in the multiple micronodular pulmonary metastases. As the serum carcinoembryonic antigen levels gradually became elevated in February 2005, we proposed treatment with gefitinib and obtained informed consent for the investigation of EGFR mutations as well. In mid-april, gefitinib therapy was started, because a heterozygous L858R EGFR mutation was demonstrated on lung tumor tissue obtained through VATS. Improvement was seen on the chest radiograph after 2 weeks. The maximum reduction in the size and numbers of multiple pulmonary metastatic foci and shrinkage of the primary tumor were achieved after 3 months of therapy (Figure 1 C, D). The only adverse effect was eruptions involving the face (especially surrounding the mouth) and the anterior chest, as observed in Patient 1. The serum carcinoembryonic antigen level had reduced from 125 ng/ml to 25 ng/ml. Major response and the continuing decrease in serum carcinoembryonic antigen level are currently evident. Mutational Analysis of Epidermal Growth Factor Receptor Genomic DNA was extracted from the tumor specimens according to the conventional method. Pleural effusion from Patient 1 and formalin-fixed paraffin-embedded lung tumor tissue obtained at VATS from Patient 2 were subjected to DNA extraction. EGFR mutations in exons 18 through 21 were examined according to the methods previously described by Lynch et al. (2); primers for EGFR (exons 18-21) analysis were the same as those reported in their paper. Nested polymerase chain reaction (PCR) amplification was conducted on the paraffin-embedded tissue sections. All sequencing reactions were performed in both the forward and reverse directions. Direct DNA sequencing on amplification products was performed using an ABI PRISM 310 genetic analyzer with a Big-Dye terminator cycle sequencing kit (Applied Biosytems, Foster City, CA, USA). All mutations were confirmed at least twice from independent amplification products. 1622
3 Kobayashi et al: Gefitinib Response and EGFR in Lung Adenocarcinoma Figure 1. (A) CT scanning of Patient 1 before gefitinib therapy shows a solitary peripheral mass and numerous multiple micronodules throughout both lungs. Apparent pleural thickening is seen adjacent to the mass. (B) CT scanning after 2 months of gefitinib therapy shows shrinkage of the mass and a remarkable reduction in the multiple nodules. (C) CT scanning of Patient 2 before gefitinib therapy shows an ill-defined mass in the middle lobe of the right lung along with widespread micronodules throughout both lungs. Pleural retraction is seen adjacent to the mass. (D) CT scanning after 3 months of gefitinib therapy shows shrinkage of the mass and remarkable reduction of the multiple nodules. Results On the CT scans, the dramatic response to gefinitib can be seen in both patients in terms of the remarkable reduction in micronodular pulmonary metastases, as shown in Figures 1 and 2. CT imaging before the start of gefitinib treatment revealed a primary solid tumor with multiple micronodular opacities in both cases. Most of the micronodules seemed to be distributed in the centrilobular region. Pathological/CT correlation could only be analyzed in Patient 2. The pathological diagnosis demonstrated welldifferentiated papillary adenocarcinoma with invasion to the parietal pleura of the right middle lobe (Figure 2A). Numerous multiple foci of bronchioloalveolar cell carcinoma-like tumor growth were seen and these were interpreted as pulmonary metastasis (Figure 2B). In the molecular studies, a heterozygous exon 19 deletion (dele746-a750) was detected in the pleural effusion from Patient 1 (Figure 3A) and a heterozygous L858R mutation was detected in the formalin-fixed paraffin-embedded lung tumor tissue from Patient 2 (Figure 3B). Although pleural effusion from Patient 1 was aspirated in the recurrence of the disease despite the continued taking of gefitinib, an acquired T790M mutation in exon 20 was not detected; this mutation was quite recently reported to have a close relation with the resistance to gefitinib (10, 11). 1623
4 Figure 2. (A) A light microscopic view of VATS tissue specimen from Patient 2 shows one of the prominent areas of a well-differentiated adenocarcinoma (H&E stain, magnification x200). (B) Bronchioloalveolar cell carcinoma features are also present in other areas of the same tumor specimen (H&E stain, magnification x200). Discussion Somatic EGFR mutations are found more frequently among patients with adenocarcinoma, non-smokers, patients of Asian ethnicity and females (4-9). The most common EGFR mutations include the E746-A750 exon 19 deletion and the missense mutation L858R exon 21. Mutations in the EGFR gene are present only in the tumor; no germline mutations have been reported (3, 4). The response to gefitinib has been reported to be closely associated with these EGFR mutations (3-5). In both of the patients studied here, multiple micronodular foci were commonly observed throughout the lungs on CT imaging. The marked reduction of these foci was seen after oral gefitinib therapy. The interpretation of diffuse multiple micronodular patterns is realistically difficult on the basis of radiological appearance without histological information. Radiologically, centrilobular distribution of micronodules on a CT scan may suggest bronchioloalveolar cell carcinoma features with the cancer cells infiltrating the cells lining the alveoli (12, 13). In fact, differentiating multiple hematogenous metastases of lung adenocarcinomas from multiple micronodular foci of bronchioloalveolar cell carcinoma cannot be done easily on chest radiographs or CT scans. In addition, a detailed pathological study of these tumors is more problematic because these tumors are unresectable and they are often diagnosed only from limited biopsy and cytology specimens (14). In our study, the histological evaluation of the lung tumor tissue of Patient 2, obtained through VATS, demonstrated well-differentiated papillary adenocarcinoma with bronchioloalveolar cell carcinoma features. Based upon the World Health Organization criteria, pure bronchioloalveolar cell carcinoma has a relatively lower incidence of EGFR mutation, while nearly all adenocarcinomas that include any areas of bronchioloalveolar cell carcinoma growth, which are sensitive to gefitinib or erlotinib and harbor EGFR mutations, have bronchioloalveolar cell carcinoma features (15). This is consistent with the clinical observation reported by Kris et al. that the response rate to erlotinib, a tyrosine kinase inhibitor similar to gefitinib, in pure bronchioloalveolar cell carcinoma was reported to be somewhat lower than that of mixed tumors or bronchioloalveolar cell carcinoma variants (16). Histological evaluation is not always feasible. Therefore, recognition of typical radiological patterns, from which to predict the response to gefitinib, is extremely useful from the clinical standpoint. We believe that the diffuse micronodular opacities observed in our cases represent the findings suggestive of invasive lung adenocarcinoma with bronchioloalveolar cell carcinoma features. Furthermore, pulmonary toxicity due to gefitinib, often seen among Japanese patients, did not occur in these responding patients; both of them were nonsmokers at the time (17). Because the most common EGFR mutations were present in both of our cases, we are convinced that the diffuse micronodular pattern of pulmonary metastasis by lung adenocarcinomas might be a novel clinical predictor of gefitinib response. However, further studies are clearly warranted. 1624
5 Kobayashi et al: Gefitinib Response and EGFR in Lung Adenocarcinoma Figure 3. (A) The EGFR mutational analysis of exon 19 in pleural effusion from Patient 1 showed a heterozygous dele746-a750 mutation. (B) The EGFR mutational analysis of exon 21 in the formalin-fixed paraffin-embedded tissue specimen from Patient 2, obtained through VATS, showed a heterozygous L858R mutation. 1625
6 References 1 Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: , Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23: , Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okomoto RA, Brannigan BW et al: Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Eng J Med 350: , Paes JG, Janne PA, Lee JC, Tracy S, Grenlich H, Gabriel S et al: EGFR mutation in lung cancer: correlation with clinical response to gefitinib therapy. Science (Washington DC) 304: , Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sakarta I et al: EGF receptor mutations are common in lung cancer from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: , Miller VA, Kris MG, Shah N, Patel J, Azzori C, Gomez J et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: , Janne PA, Enelman JA and Johnson BE: Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23: , Kosaka T. Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the EGFR gene in lung cancer: biological and clinical implications. Cancer Res 64: , Huang S-F, Liu H-P, Li L-H, Ku Y-C, Fu Y-N, Tsai H-Y et al: High frequency of EGFR mutations with complex patterns in NSCLC related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: , Kobayashi S, Boggen TJ, Dayaram T, Janne PA, Koeler O, Meyerson M et al: EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Eng J Med 352: , Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: , Webb WR, Muller NL and Naidich DP: High Resolution CT of the Lung. 2nd ed. Philadelphia/New York: Lippincott-Raven Publishers, Akira M, Atagi S, Iuchi K and Johko T: High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients. AJR 173: , Travis WD, Garg K, Franklin WA, Wistuba II, Sabaloff B, Noguchi M et al: Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 23: , Miller VA, Hirsh FR and Johnson DH: Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol 23: , Kris MG, Sandler A, Miller, Cespon M, Zakwski M, Pizzo B et al: Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). Proc Am Soc Clin Oncol 23: 628S, Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T and Nukiwa T: Severe acute interstitial pneumonia and gefitinib. Lancet 361: , Received December 5, 2005 Accepted January 26,
The epidermal growth factor receptor (EGFR) is recognized as an important molecular target in cancer therapy. 1
Association of Diffuse, Random Pulmonary Metastases, Including Miliary Metastases, With Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma Yosuke Togashi, MD 1 ; Katsuhiro Masago, MD, PhD
More informationEGFR, Lung Cancer and Cytology. Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan.
EGFR, Lung Cancer and Cytology Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan. It is histopathologically divided into two major sub-groups: Small
More informationA Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma
Jpn J Clin Oncol 26;36(2)69 75 doi:.93/jjco/hyi228 Original Articles A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma Hiroshi
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationONCOLOGY LETTERS 8: , 2014
ONCOLOGY LETTERS 8: 813-818, 2014 Investigation of the epidermal growth factor receptor mutation rate in non small cell lung cancer patients and the analysis of associated risk factors using logistic regression
More informationLung cancer is the most common cause of cancer death in
ORIGINAL ARTICLE Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features? Catherine
More informationExon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
Case Report Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report Yu-Ting Wang, Wei-Wei Ning, Jing Li, Jian-n Huang Department of Respiratory Medicine, the First ffiliated
More informationRepeated Favorable Responses to Epidermal Growth Factor Receptor- Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
http://dx.doi.org/10.4046/trd.2013.74.3.129 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;74:129-133 CopyrightC2013. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More informationThe Spectrum of Management of Pulmonary Ground Glass Nodules
The Spectrum of Management of Pulmonary Ground Glass Nodules Stanley S Siegelman CT Society 10/26/2011 No financial disclosures. Noguchi M et al. Cancer 75: 2844-2852, 1995. 236 surgically resected peripheral
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationLi et al. BMC Genetics (2015) 16:20 DOI /s
Li et al. BMC Genetics (2015) 16:20 DOI 10.1186/s12863-015-0181-4 RESEARCH ARTICLE Open Access Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and
More informationThe ABCs of BAC: Bronchioloalveolar Carcinoma
The ABCs of BAC: Bronchioloalveolar Carcinoma Howard (Jack) West, MD Medical Oncologist Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA March, 2009 President & CEO GRACE
More informationRetrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More informationAnalysis of the EGFR gene mutation in patients with nonsmall cell lung cancer in a Chinese population
Tropical Journal of Pharmaceutical Research August 2016; 15 (8): 1637-1641 ISSN: 1596-5996 (print); 1596-9827 (electronic) Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001
More informationCASE REPORT. Abstract. Introduction. Case Report
SE REPORT n utopsy ase of Two Distinct, cquired Drug Resistance Mechanisms in Epidermal Growth Factor Receptor-mutant Lung denocarcinoma: Small ell arcinoma Transformation and Epidermal Growth Factor Receptor
More informationGTS. Earn CME credits at
Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center Sandra P. D Angelo, MD, Bernard Park,
More informationTarceva. Tarceva (erlotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.82 Subject: Tarceva Page: 1 of 5 Last Review Date: June 22, 2018 Tarceva Description Tarceva (erlotinib)
More informationLung cancer is the leading cause of cancer-related
Original Articles Correlation of Mutation Status With Predominant Histologic Subtype of Adenocarcinoma According to the New Lung Adenocarcinoma Classification of the International Association for the Study
More informationClinical Study The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases
Pulmonary Medicine Volume 2011, Article ID 290132, 5 pages doi:10.1155/2011/290132 Clinical Study The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationAuthor's response to reviews
Author's response to reviews Title: Evaluation of Safety and Efficacy of Gefitinib ('Iressa', ZD1839) as Monotherapy in a series of Chinese Patients with Advanced Non-small-cell Lung Cancer: Experience
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationSomatic, activating mutations in epidermal growth factor
Brief Report Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort Helena A. Yu, MD,* Maria E. Arcila, MD, Megan Harlan Fleischut, MS, Zsofia Stadler, MD, Marc Ladanyi, MD, Michael
More informationExpert Round Table with Drs. Anne Tsao and Alex Farivar Part 1: Elderly Man with Indolent Bronchioloalveolar Carcinoma
Expert Round Table with Drs. Anne Tsao and Alex Farivar Part 1: Elderly Man with Indolent Bronchioloalveolar Carcinoma February 2010 I d like to welcome everyone, thanks for coming out to our lunch with
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationThe epidermal growth factor receptor (EGFR) is a promising
ORIGINAL ARTICLE Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer
More informationThoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis
19 th Congress of APSR PG of Lung Cancer (ESAP): Update of Lung Cancer Thoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis Kazuma Kishi, M.D. Department of Respiratory Medicine,
More informationOBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.
Organ Imaging : September 25 2015 OBJECTIVES Case Based Discussion: State of the Art Management of Lung Nodules Dr. Elsie T. Nguyen Dr. Kazuhiro Yasufuku 1. To review guidelines for follow up and management
More informationThe estimation of tumor cell percentage for molecular testing by pathologists is not accurate
168 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The estimation of tumor cell percentage for molecular testing by pathologists is not accurate Alexander JJ Smits 1,2, J Alain Kummer 1, Peter
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationClinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
Jpn J Clin Oncol 2012;42(6)528 533 doi:10.1093/jjco/hys042 Advance Access Publication 28 March 2012 Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More informationCT findings in multifocal or diffuse non-mucinous bronchioloalveolar carcinoma (BAC)
CT findings in multifocal or diffuse non-mucinous bronchioloalveolar carcinoma (BAC) Poster No.: C-2192 Congress: ECR 2014 Type: Educational Exhibit Authors: I. Sandu, A. R. Popita, I.-A. Brumboiu; Cluj-Napoca/RO
More informationSleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department
More informationCT findings in multifocal or diffuse non-mucinous bronchioloalveolar carcinoma (BAC)
CT findings in multifocal or diffuse non-mucinous bronchioloalveolar carcinoma (BAC) Poster No.: C-2192 Congress: ECR 2014 Type: Educational Exhibit Authors: I. Sandu, A. R. Popita, I.-A. Brumboiu; Cluj-Napoca/RO
More informationWell-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report
Showa Univ J Med Sci 25 1, 67 72, March 2013 Case Report Well-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report Yuri TOMITA
More informationSteering Committee. Waiting on photo. Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD.
Steering Committee Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD MD, PhD Waiting on photo Paul Van Schil, MD, PhD William D. Travis, MD Ming-Sound Tsao,
More informationCT Screening for Lung Cancer for High Risk Patients
CT Screening for Lung Cancer for High Risk Patients The recently published National Lung Cancer Screening Trial (NLST) showed that low-dose CT screening for lung cancer reduces mortality in high-risk patients
More informationKey Words. Lung cancer EGFR Mutation Genetic screening
The Oncologist Lung Cancer Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing LECIA V. SEQUIST, VICTORIA A. JOSHI, PASI A. JÄNNE, ALONA
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationQuality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationA case of different EGFR mutations in surgically resected synchronous triple lung cancer
Case Report A case of different EGFR mutations in surgically resected synchronous triple lung cancer Naoki Haratake 1, Mitsuhiro Takenoyama 1, Makoto Edagawa 1, Shinichiro Shimamatsu 1, Ryo Toyozawa 1,
More informationGuide to Understanding Lung Cancer
Guide to Understanding Lung Cancer Lung cancer is the second most common cancer overall for men and women in the U.S., with an estimated 222,500 new cases in 2017. However, lung cancer is the most common
More informationTreatment of non-small cell lung carcinoma with gefitinib: a case report
Treatment of non-small cell lung carcinoma with gefitinib: a case report A. Lefebure, P. Germonprè Targeted therapy for non-small cell lung carcinoma (NSCLC) is a possible treatment option for patients
More informationUC Irvine UC Irvine Previously Published Works
UC Irvine UC Irvine Previously Published Works Title Epidemiology of bronchioloalveolar carcinoma: Improvement in survival after release of the 1999 WHO classification of lung tumors Permalink https://escholarship.org/uc/item/0sc2k36f
More informationNon Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationA case of multiple synchronous lung adenocarcinomas with differing EGFR mutations
Int Canc Conf J (2013) 2:224 228 DOI 10.1007/s13691-013-0096-8 CASE REPORT A case of multiple synchronous lung adenocarcinomas with differing EGFR mutations Hideomi Hasegawa Hideki Kimura Masato Shingyoji
More informationLung Cytology: Lessons Learned from Errors in Practice
Lung Cytology: Lessons Learned from Errors in Practice Stephen S. Raab, M.D. Department of Laboratory Medicine Eastern Health and Memorial University of Newfoundland, St. John s, NL and University of Washington,
More informationLung cancer is the leading cause of cancer death worldwide.
ORIGINAL ARTICLE Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival
More informationQuality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE:
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationKRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Open access, freely available online KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib PLoS MEDICINE William Pao 1,2*, Theresa Y. Wang 1, Gregory J. Riely 2, Vincent
More informationEfficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer
Original Article Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer Aiqin Gu, Chunlei Shi, Liwen Xiong, Tianqing Chu, Jun Pei, Baohui Han Department of pulmonary
More informationDan Liu 1., Yachao Lu 2., Zhenli Hu 1., Ning Wu 1, Xiaomeng Nie 1, Yang Xia 1, Yiping Han 1, Qiang Li 1, Guanshan Zhu 2, Chong Bai 1 * Abstract
Malignant Pleural Effusion Supernatants Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients with Advanced Lung Adenocarcinoma Dan Liu 1., Yachao Lu 2., Zhenli Hu 1.,
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationMOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE
25 th IAP-Arab Division Conference 07-09 November 2013, Amman, Jordan MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE Fouad Al Dayel, MD, FRCPA, FRCPath Professor and Chairman Department
More informationSUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
More informationINTRODUCTION. Key words: Gefitinib, EGFR-tyrosine kinase inhibitors, Non Small Cell Lung Cancer
Gefitinib (Iressa) in Non Small Cell Lung Cancer at Kuwait Cancer Control Centre Experience, Kuwait, with Focus on Future Use of EGFR- Tyrosine Kinase Inhibitors Vinay Vyas, Al-Awadi Shafika, Jarslov N,
More informationEGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.48 EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung Tae Won Jang 1, Chul Ho Oak 1, Hee Kyung Chang 2, Soon Jung Suo 3 and Mann Hong Jung
More informationRecent advances in high-resolution computed tomography
ORIGINAL ARTICLE Epidermal Growth Factor Receptor Mutations in Multicentric Lung Adenocarcinomas and Atypical Adenomatous Hyperplasias Koei Ikeda, MD, PhD,* Hiroaki Nomori, MD, PhD,* Yasuomi Ohba, MD,*
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationSuccessful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
doi: 10.2169/internalmedicine.8947-17 http://internmed.jp CASE REPORT Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease Tatsunori Kiriu, Daisuke
More informationYong Zhang 1#, Ling Ye 1#, Huijun Zhang 1, Xuehua Chen 1, Haiying Ji 1, Gang Chen 1, Lu Zhang 2, Tengfei Zhang 2, Meiling Jin 1.
Case Report A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors Yong Zhang 1#, Ling Ye 1#,
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationRESEARCH ARTICLE. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
RESEARCH ARTICLE EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer Satoshi Igawa 1 *, Yuichi Sato 2, Mikiko Ishihara 1, Masashi Kasajima
More informationPlatinum-based doublets are considered to be the standard
Blackwell Publishing Asia Review Article Recent trends in the treatment of advanced lung cancer Nagahiro Saijo 1 National Cancer Center, Hospital East, Kashiwanoha 6-5-1, Kashiwa-shi, Chiba 277-8577, Japan
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationNon-Small Cell Lung Carcinoma - Myers
Role of Routine Histology and Special Testing in Managing Patients with Non- Small Cell Lung Carcinoma Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of
More informationIntroduction ORIGINAL ARTICLE
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective
More informationRegulatory Issues - FDA
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Regulatory Issues - FDA FDA Drug Approval Summary: Erlotinib
More informationCytotoxic chemotherapy such as carboplatin (CBDCA)
ORIGINAL ARTICLE Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Hironori Satoh, MD, PhD,* Akira Inoue,
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationAn Interactive Guide to ALK+ Lymphoma. Our understanding of lung cancer has changed From one disease to many subtypes LCD
An Interactive Guide to ALK+ Anaplastic Lymphoma Kinase Non-Small Cell Lung (NSCLC) Our understanding of lung cancer has changed From one disease to many subtypes Click to get started Learning about Lung
More informationTest Category: Prognostic and Predictive. Clinical Scenario
Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy Test Category: Prognostic
More informationTyrosine kinase inhibitors (TKIs) of the epidermal growth
ORIGINAL ARTICLE Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib Tatsuya Katayama, MD,* Junichi Shimizu,
More informationDiagnostics guidance Published: 14 August 2013 nice.org.uk/guidance/dg9
EGFR-TK mutation testing in adults with locally advanced or metastatic non-small- cell lung cancer Diagnostics guidance Published: 14 August 2013 nice.org.uk/guidance/dg9 NICE 2018. All rights reserved.
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationLung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers
Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers The Harvard community has made this article openly available. Please share how this access
More informationA nonresponding small cell lung cancer combined with adenocarcinoma
Case Report A nonresponding small cell lung cancer combined with adenocarcinoma Hongyang Lu 1,2, Shifeng Yang 3 1 Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung
More informationCHAPTER 8A. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases one with a remarkable thoracic response as well
CHAPTER 8A High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases one with a remarkable thoracic response as well J.L. Kuiper, E.F. Smit Lung Cancer 2013 Apr;80(1):102-5 Chapter
More informationAdditional clinical features of this patient include:
*Not an actual patient. Challenge your knowledge of biomarker testing in advanced NSCLC. Consider this case study of disease progression following chemotherapy, with insightful commentary from Dr Edward
More informationTHE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS
THE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS PULMONARY PATHOLOGY SOCIETY USCAP, BALTIMORE, March 2, 2013 William D. Travis, M.D. Dept of Pathology, Memorial Sloan-Kettering Cancer
More informationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy J. Guillermo Paez, 1,2* Pasi A. Jänne, 1,2* Jeffrey C. Lee, 1,3* Sean Tracy, 1 Heidi Greulich, 1,2 Stacey Gabriel,
More informationPersistent Spontaneous Pneumothorax for Four Years: A Case Report
303) Persistent Spontaneous Pneumothorax for Four Years: A Case Report Mizuno Y., Iwata H., Shirahashi K., Matsui M., Takemura H. Department of General and Cardiothoracic Surgery, Graduate School of Medicine,
More information8/22/2016. Major risk factors for the development of lung cancer are: Outline
Carcinomas of the Lung: Changes in Staging, Adenocarcinoma Classification and Genetics Grace Y. Lin, M.D., Ph.D. Outline Background Staging of Lung Cancer: Review of the 2010 7 th Edition of the AJCC Cancer
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationDiagnostic challenge: Sclerosing Hemangioma of the Lung. Department of Medicine, Division of Pulmonary and Critical Care, Lincoln Medical and
Diagnostic challenge: Sclerosing Hemangioma of the Lung. S. Arias M.D, R. Loganathan M.D, FCCP Department of Medicine, Division of Pulmonary and Critical Care, Lincoln Medical and Mental Health Center/Weill
More informationComparison of High-resolution CT Findings between Miliary Metastases and Miliary Tuberculosis 1
Comparison of High-resolution CT Findings between Miliary Metastases and Miliary Tuberculosis 1 Chan Sung Kim, M.D., Ki-Nam Lee, M.D., Jin Hwa Lee, M.D. Purpose: To compare the findings of high-resolution
More informationManagement of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma
ORIGINAL ARTICLE Management of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma Hong Kwan Kim, MD,* Yong Soo Choi, MD,* Jhingook Kim, MD, PhD,* Young Mog Shim, MD,
More informationGround Glass Opacities
Ground Glass Opacities A pathologist s perspective Marie-Christine Aubry, M.D. Professor of Pathology Mayo Clinic Objectives Discuss the proposed new pathologic classification of adenocarcinoma with historical
More information